



PATENT
ATTORNEY DOCKET NO. JHU1710-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James E. Hildreth
Serial No.: 09/802,779
Filed: March 8, 2001
Title: β -CYCLODEXTRIN COMPOSITIONS, AND USE TO PREVENT
TRANSMISSION OF SEXUALLY TRANSMITTED DISEASES

Art Unit: 1623
Examiner: P.T. Lewis
Conf. No.: 9936

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER


Sir:

The undersigned attorney of record for Petitioners, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, a non-profit organization, with its place of business at 100 N. Charles Street, 5th Floor, Baltimore, MD 21201, represents that Petitioners are the Owners of 100 percent interest in Application No. 09/802,779, filed March 8, 2001, entitled β -CYCLODEXTRIN COMPOSITIONS, AND USE TO PREVENT TRANSMISSION OF SEXUALLY TRANSMITTED DISEASES, as evidenced by the Assignment recorded in the United States Patent and Trademark Office on February 11, 2002, at Reel 012609, Frame 0464 (3 pages).

10/08/2003 DTESSEM1 00000152 09802779

01 FC:2814

55.00 OP

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, October 1, 2003 , in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Aldon Griffis (Name of Person Mailing Paper)	
 (Signature)	October 1, 2003 (Date)

In the Application of:
James E. Hildreth
Application No.: 09/802,779
Filed: March 8, 2001
Page 2

PATENT
Attorney Docket No. JHU1710-3

The undersigned, attorney of record further represents that THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, a non-profit organization, with its place of business at 100 N. Charles Street, 5th Floor, Baltimore, MD 21201, is the Owner of 100 percent interest in U.S. Patent Application No. 09/801,393, entitled β -CYCLODEXTRIN COMPOSITIONS, AND USE TO PREVENT TRANSMISSION OF SEXUALLY TRANSMITTED DISEASES, as evidenced by the Assignment recorded in the United States Patent and Trademark Office on September 6, 2001, at Reel 012138, Frame 0685 (3 pages).

The evidentiary documents referred to herein have been reviewed by the undersigned and it is certified that to the best of the undersigned's knowledge and belief, title is in the Owners as set forth above.

Pursuant to 37 C.F.R. § 1.321(c), the undersigned, on behalf of Petitioners, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, disclaims the terminal part of any patent granted on the above-identified Application No. 09/802,779 which would extend beyond the expiration date of a patent that issues from U. S. Patent Application No. 09/801,393. Petitioners hereby agree that any patent so granted on the above-identified application No. 09/802,779 shall be enforceable only for and during such period that said patent and a patent issuing from U.S. Patent Application No. 09/801,393 are commonly owned, this Agreement to run with any patent granted on the above-identified application and to be binding upon the grantees, its successor or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently

In the Application of:
James E. Hildreth
Application No.: 09/802,779
Filed: March 8, 2001
Page 3

PATENT
Attorney Docket No. JHU1710-3


shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and believe are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Check No. 545401 in the amount of \$55.00 is enclosed for the Terminal Disclaimer fee and any other fees that may be associated with this communication, or credit any overpayment to Deposit Account No. 50-1355. A copy of the Transmittal Sheet is enclosed.

Respectfully submitted,

Date: October 1, 2003



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
USPTO Customer Number 28213